GENOSCIENCE PHARMA Announces Remarkable Data on GNS561 in Combination with anti-PD1 to be Presented at the AACR Annual Meeting 2020. Calidi Biotherapeutics is headquartered in San Diego, California. We are grateful to everyone—including the attendees, speakers, and sponsors—who made the AACR Virtual Annual Meeting I such a success. The platform is based on a chemically modified carrier protein that can be conjugated to protein therapeutics, such as antibodies or enzymes, and is designed to deliver the conjugated therapeutic inside cells thus providing access to numerous, critical disease targets currently considered “undruggable”. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, announced today that data from clinical studies on their oncolytic agent, CAL1 vaccinia virus, and stem cell delivery system will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting II, which will be held in virtual format June 22 through June 24, 2020, due to COVID-19 concerns. You can change your choices at any time by visiting Your Privacy Controls. The session videos from the AACR Virtual Annual Meeting II are available for on-demand viewing through the Virtual Meeting platform until September 30. Despite the negative impacts of COVID-19 upon society and patients with cancer, the pandemic has hastened innovative changes to cancer care that are transforming patient access to treatments and clinical trials. To further refine your search, toggle appropriate sections on or off. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania. No forward-looking statement can be guaranteed. NCI invites AACR 2020 attendees to participate in a virtual presentation where study coordinators will review the objectives of NCCAPS and explain how you can participate in this important study. Details about the Virtual Meeting II are provided below: We look forward to your participation in the AACR Virtual Annual Meeting II, and we hope that you will consider a donation to the AACR to support our efforts to turn lifesaving science into patient care.
Telephone: 215-440-9300 Press/Investor Contact: Steve Thesing A rescheduled meeting is being planned for later this year. Calidi’s off-the-shelf, universal cell-based delivery platform is designed to protect, amplify, and potentiate oncolytic viruses currently in development leading to enhanced efficacy and improved patient safety. Biond Biologics is a drug discovery and development company focused on developing innovative therapies for novel oncology targets by uncovering immunoregulatory pathways and by enabling the intracellular delivery of biologics. AACR Virtual Annual Meeting II: Sessions available for viewing Visit the Meeting Site View all concurrent sessions with the printable Program at a Glance Download Now Create a personal itinerary for the Virtual Annual Meeting II (meeting registrants only) Access the Itinerary Planner Both abstracts indicate significant advantages and fundamental rationale for the development of vehicles like Calidi’s cell-based delivery platform (https://calidibio.com/our-science/), designed to protect and potentiate oncolytic viruses by circumventing innate and adaptive immune barriers, resulting in enhanced oncolytic virotherapy. On April 6, due to the rapid escalation of the COVID-19 pandemic, the AACR Board of Directors made the decision not to move forward with an in-person Annual Meeting in August, and instead to present segments of the meeting program in two AACR Virtual Annual Meetings. AACR 2020 Virtual Annual Meeting. For more information, please visit www.biondbio.com. These risks and uncertainties include market conditions and other factors beyond the Company’s control. The AACR is dedicated to the rapid dissemination of innovative cancer research that has always been the hallmark of our Annual Meetings—and to making that research as widely accessible as possible during this global pandemic. This special AACR conference focused on the presentation of emerging data in basic, clinical, and epidemiologic research related to COVID-19 and cancer. AACR Virtual Annual Meeting 2020: Selected Presentations / Other Free Resources Posted March 31, 2020 The AACR is planning to reschedule the Annual Meeting for late August while at the same time closely monitoring the developments surrounding COVID-19. The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world. The AACR Virtual Annual Meeting II will include an Opening Plenary Session, the Presidential Select Symposium, and a complete educational program. Users who have not yet registered will be required to create an account upon visiting the Virtual Meeting platform. The increased incidence of severe COVID-19 in certain ethnic backgrounds and association with socioeconomic disparities was highlighted in several sessions; including the virtual poster session.
We will be sending detailed information about the virtual program soon. The AACR and The Rivkin Center for Ovarian Cancer have also made the difficult decision to cancel the following meeting: 13 th Biennial Ovarian Cancer Research Symposium presented by the Rivkin Center for Ovarian Cancer and the American Association for Cancer Research (September 26 … American Association for Cancer Research 2020 Virtual Meeting II. Find out more about how we use your information in our Privacy Policy and Cookie Policy. Calidi’s study on the immunomodulatory potential of vaccinia virus delivered by autologous SVF-derived cells expanded on their recent first-in-human Phase I clinical trial, which confirmed the safety and feasibility of their approach for improving virus delivery and tumor targeting. We look forward to exploring the clinical potential of ILT2 blockade in the upcoming, first-in-human clinical trial of our lead drug candidate BND-22.”, Jeff Weber, M.D., Ph.D., Deputy Director, Perlmutter Cancer Center, NYU Langone Medical Center, and member of Biond’s Scientific Advisory Board added, “The data indicating that proteolytic cleavage and subsequent shedding of the critical CD28 immuno-regulatory receptor results in inhibition of CD8 lymphocytes is exciting, as it may represent an important mechanism by which resistance to PD-1 blockade therapies develops. BND-22 has been shown in preclinical studies to have a broad anti-tumor effect by targeting ILT2 mediated “do not eat me” signals in macrophages and by activating NK and CD8+ lymphocytes. The company’s vision is to deliver innovative medicines to patients while fostering synergistic long-term collaborations with leading biopharmaceutical companies. The 2020 American Association for Cancer Research (AACR) annual meeting is being held virtually in April and June. July 20-22, 2020. Biond aims to translate high quality science and out-of-the-box, disruptive thinking into transformational drugs for diseases with high unmet needs. This study establishes a timeline of treatment-related immunological changes, identifies potential immunological correlations with continued amplified oncolytic therapy, and provides insights into the role of interpatient immunological variability and future oncolytic virotherapy evaluation. Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at AACR 2020 Virtual Annual Meeting II June 22, 2020 09:00 AM Eastern Daylight Time. Recently published articles from the AACR journals relating to COVID-19 are freely available. MISGAV, Israel, July 09, 2020 (GLOBE NEWSWIRE) -- Biond Biologics Ltd. (“Biond” or the “Company”), a privately-held biopharmaceutical company, developing novel immunotherapies for cancer and a platform enabling the intracellular delivery of biologics, today announced that data highlighting the development of BND-22, a first-in-class anti-Ig-like transcript 2 (ILT2) antibody, and CD28 shedding as a novel cancer immunotherapy target, were presented at the 2020 American Association of Cancer Research (AACR) Virtual Annual Meeting II, held June 22-24, 2020. Date: June 22, 2020, from 9:00 AM to 6:00 PM, Abstract 4473: Evaluation of the potential of oncolytic vaccinia virus delivered by autologous SVF to modulate innate and adaptive immunity in patients with diverse solid and hematological malignancies The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements.
Senior Vice President Additional information regarding hotel reservation cancellations, registration refunds, and meeting logistics is available on the FAQ page on the AACR website. To further refine your search, toggle appropriate sections on or off. This conference will focus on the presentation of broad areas of interest in basic, translational and clinical research related to COVID-19 and cancer. David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, Dafna Bar-Sagi, New York University Langone Medical Center, New York, New YorkJohn M. Carethers, University of Michigan, Ann Arbor, MichiganGypsyamber D’Souza, Johns Hopkins University, Baltimore, MarylandKeith T. Flaherty, Massachusetts General Hospital, Boston, MassachusettsMarina Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, ItalyElizabeth M. Jaffee, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MarylandKaren E. Knudsen, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PennsylvaniaAntoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, CaliforniaE. The safety, tolerability, and anti-tumor activity of BND-22 will be explored in a first-in-human clinical trial in cancer patients with tumor types known to express HLA-G. Company Contact:Itay Friedman, M.D.VP Clinical DevelopmentBiond Biologics Ltd.+972-4 884 4337itay@biondbio.com. Posted March 10, 2020 The American Association for Cancer Research (AACR) Board of Directors has made the difficult decision, after careful consideration and comprehensive evaluation of currently available information related to the novel coronavirus (COVID-19) outbreak, to terminate the AACR Annual Meeting 2020, originally scheduled for April 24-29 in San Diego, California. Details of the presentations are as follows: Title: BND-22, a first-in-class, anti-ILT2 monoclonal antibody inhibits the immunosuppressive effects of HLA-G and enhances anti-tumor activity of immune cells in preclinical in vitro, ex vivo, and in vivo modelsSession: Immune Checkpoints 3Poster Number: 3266Presentation Type: E-posterhttps://www.abstractsonline.com/pp8/#!/9045/presentation/8499, Title: CD28 shedding is a novel immune-regulatory mechanism found in cancer patients which directly inhibits anti PD-1 effectSession: Tumor-immune System Interactions 2Poster Number: 2846APresentation Type: E-posterhttps://www.abstractsonline.com/pp8/#!/9045/presentation/9307, “We were excited to present these data at the 2020 AACR, further demonstrating our team’s ability to discover novel immuno-regulatory targets and develop novel therapies for cancer patients,” said Tehila Ben Moshe, Ph.D., Chief Executive Officer and Chairperson at Biond. COVID-19 has encouraged innovation by cancer investigators to address this pandemic, including new diagnostic assays using nucleotide sequencing and serologic methods that were previously developed to study cancer; the development of new virus-targeted drugs based on the knowledge of COVID-19 proteins as has been done for years with targeted therapies for cancer; the testing of next-generation vaccines with similar principles as cancer vaccines; and the use of repurposed oncology drugs to treat COVID-19 patients. 615 Chestnut St., 17th Floor